Skip to main content
Fig. 10 | Journal of Translational Medicine

Fig. 10

From: Prevention of neointimal hyperplasia after coronary artery bypass graft via local delivery of sirolimus and rosuvastatin: network pharmacology and in vivo validation

Fig. 10

Sirolimus and rosuvastatin regulate MMP expression in the chronic stages via Akt/mTOR/NF-kB signaling. A–F Protein levels of Akt1, mTOR, p-mTOR, NF-κB, and MMP9 were detected via western blot analysis. Data are presented as the mean ± standard error of mean. Statistical significance was determined using Fisher’s least significant difference test (*p < 0.05, **p < 0.01, ***p < 0.001). SIR + RSV combination of sirolimus and rosuvastatin, Akt a protein cloned from the v-akt oncogene of retrovirus AKT8, mTOR mammalian target of rapamycin, p-mTOR phosphorylated mTOR, NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells, MMP matrix metalloproteinase

Back to article page